Cell Therapies P/L has become an essential partner in the recently approved Cooperative Research Center for Cell Therapies Manufacturing (CRC-CTM). The combination of world leading academic researchers with local and overseas commercial companies is a novel feature of the Australian Government sponsored CRC program.
The CRC-CTM’s research is directed towards improved manufacturing capabilities and lowered cost of goods (COGS). Targeted clinical indications include unresolved diabetic foot ulcers, Graft vs Host disease (GvHD) for transplant patients, type 2 diabetes and diseases of the immune system where T-cells are involved.
Cell Therapies P/L will provide the regulatory compliant environment that facilitates the migration of CRC-CTM research into the clinic. A feature of this CRC is the seamless integration of pure research with commercial scale reduction to practice via first in man and subsequent routine treatments.
To reach out to our expert team, enter your details and we will arrange a call at a time that suits you.